Updated cancer treatment framework offers new guidance on actionability and resistance biomarkers

ESMO has published mentation 2 of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), a large update to the internationally recognized precision oncology model that helps oncologists measure the objective relevance of molecular alterations and lucifer patients with the astir due targeted therapies.